376 related articles for article (PubMed ID: 34063789)
1. Mast Cells: A New Frontier for Cancer Immunotherapy.
Lichterman JN; Reddy SM
Cells; 2021 May; 10(6):. PubMed ID: 34063789
[TBL] [Abstract][Full Text] [Related]
2. Mast cells as targets for immunotherapy of solid tumors.
Oldford SA; Marshall JS
Mol Immunol; 2015 Jan; 63(1):113-24. PubMed ID: 24698842
[TBL] [Abstract][Full Text] [Related]
3. Mast Cells in the Tumor Microenvironment.
Aponte-López A; Muñoz-Cruz S
Adv Exp Med Biol; 2020; 1273():159-173. PubMed ID: 33119881
[TBL] [Abstract][Full Text] [Related]
4. Toll-like receptor-targeted particles: A paradigm to manipulate the tumor microenvironment for cancer immunotherapy.
Tran TH; Tran TTP; Truong DH; Nguyen HT; Pham TT; Yong CS; Kim JO
Acta Biomater; 2019 Aug; 94():82-96. PubMed ID: 31129358
[TBL] [Abstract][Full Text] [Related]
5. Targeting KIT on innate immune cells to enhance the antitumor activity of checkpoint inhibitors.
Stahl M; Gedrich R; Peck R; LaVallee T; Eder JP
Immunotherapy; 2016 Jun; 8(7):767-74. PubMed ID: 27349976
[TBL] [Abstract][Full Text] [Related]
6. Mast Cells and Skin and Breast Cancers: A Complicated and Microenvironment-Dependent Role.
Hanes MR; Giacomantonio CA; Marshall JS
Cells; 2021 Apr; 10(5):. PubMed ID: 33922465
[TBL] [Abstract][Full Text] [Related]
7. In vivo cancer vaccination: Which dendritic cells to target and how?
Chiang CL; Kandalaft LE
Cancer Treat Rev; 2018 Dec; 71():88-101. PubMed ID: 30390423
[TBL] [Abstract][Full Text] [Related]
8. Mast cell: insight into remodeling a tumor microenvironment.
Liu J; Zhang Y; Zhao J; Yang Z; Li D; Katirai F; Huang B
Cancer Metastasis Rev; 2011 Jun; 30(2):177-84. PubMed ID: 21267769
[TBL] [Abstract][Full Text] [Related]
9. TLR-mediated metabolic reprogramming in the tumor microenvironment: potential novel strategies for cancer immunotherapy.
Huang L; Xu H; Peng G
Cell Mol Immunol; 2018 May; 15(5):428-437. PubMed ID: 29553135
[TBL] [Abstract][Full Text] [Related]
10. Differential TLR-induced cytokine production by human mast cells is amplified by FcɛRI triggering.
Suurmond J; Dorjée AL; Knol EF; Huizinga TW; Toes RE
Clin Exp Allergy; 2015 Apr; 45(4):788-96. PubMed ID: 25665021
[TBL] [Abstract][Full Text] [Related]
11. Role of mast cells activation in the tumor immune microenvironment and immunotherapy of cancers.
Guo X; Sun M; Yang P; Meng X; Liu R
Eur J Pharmacol; 2023 Dec; 960():176103. PubMed ID: 37852570
[TBL] [Abstract][Full Text] [Related]
12. Expression of costimulatory and inhibitory receptors in FoxP3
Toker A; Ohashi PS
Adv Cancer Res; 2019; 144():193-261. PubMed ID: 31349899
[TBL] [Abstract][Full Text] [Related]
13. Toll-like receptor triggering augments activation of human mast cells by anti-citrullinated protein antibodies.
Suurmond J; Rivellese F; Dorjée AL; Bakker AM; Rombouts YJ; Rispens T; Wolbink G; Zaldumbide A; Hoeben RC; Huizinga TW; Toes RE
Ann Rheum Dis; 2015 Oct; 74(10):1915-23. PubMed ID: 24818634
[TBL] [Abstract][Full Text] [Related]
14. The "Trojan Horse" approach to tumor immunotherapy: targeting the tumor microenvironment.
Nelson D; Fisher S; Robinson B
J Immunol Res; 2014; 2014():789069. PubMed ID: 24955376
[TBL] [Abstract][Full Text] [Related]
15. Harnessing the Power of Mast Cells in unconventional Immunotherapy Strategies and Vaccine Adjuvants.
Willows S; Kulka M
Cells; 2020 Dec; 9(12):. PubMed ID: 33352850
[TBL] [Abstract][Full Text] [Related]
16. Damage-associated molecular patterns and Toll-like receptors in the tumor immune microenvironment.
Yanai H; Hangai S; Taniguchi T
Int Immunol; 2021 Nov; 33(12):841-846. PubMed ID: 34357403
[TBL] [Abstract][Full Text] [Related]
17. Enhancing the Safety and Efficacy of Food Allergy Immunotherapy: a Review of Adjunctive Therapies.
Virkud YV; Wang J; Shreffler WG
Clin Rev Allergy Immunol; 2018 Oct; 55(2):172-189. PubMed ID: 29968170
[TBL] [Abstract][Full Text] [Related]
18. Application potential of toll-like receptors in cancer immunotherapy: Systematic review.
Shi M; Chen X; Ye K; Yao Y; Li Y
Medicine (Baltimore); 2016 Jun; 95(25):e3951. PubMed ID: 27336891
[TBL] [Abstract][Full Text] [Related]
19. Mast cells elicit proinflammatory but not type I interferon responses upon activation of TLRs by bacteria.
Dietrich N; Rohde M; Geffers R; Kröger A; Hauser H; Weiss S; Gekara NO
Proc Natl Acad Sci U S A; 2010 May; 107(19):8748-53. PubMed ID: 20421474
[TBL] [Abstract][Full Text] [Related]
20. Toll-Like Receptor 2 at the Crossroad between Cancer Cells, the Immune System, and the Microbiota.
Di Lorenzo A; Bolli E; Tarone L; Cavallo F; Conti L
Int J Mol Sci; 2020 Dec; 21(24):. PubMed ID: 33321934
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
